Last reviewed · How we verify

Adcetris (brentuximab-vedotin)

Pfizer · FDA-approved approved Monoclonal antibody Verified Quality 72/100

Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.

Adcetris (brentuximab-vedotin) is a CD30-directed immunoconjugate originally developed by Seattle Genetics. It targets tubulin beta and works by delivering a toxic payload to cancer cells that express CD30. Adcetris is approved to treat various types of lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, and Hodgkin's disease. The commercial status of Adcetris is patented, and it is owned by Seattle Genetics. Key safety considerations include potential side effects such as peripheral neuropathy and infusion reactions.

At a glance

Generic namebrentuximab-vedotin
SponsorPfizer
Drug classCD30-directed Immunoconjugate [EPC]
TargetTubulin beta
ModalityMonoclonal antibody
Therapeutic areaOncology
PhaseFDA-approved
First approval2011
Annual revenue900

Mechanism of action

CD30 is member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation.Brentuximab vedotin is an ADC. The antibody is chimeric IgG1 directed against CD30. The small molecule, MMAE, is microtubule-disrupting agent. MMAE is covalently attached to the antibody via linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic death of the cells. Additionally, in vi

Approved indications

Boxed warnings

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: